CloseClose
Find a Drug
Advanced Search

Professional

Crixivan

Clinical Pharmacology
font size

Clinical Pharmacology

Crixivan

Study 006 (10/15/93-10/12/94) was a dose-ranging study in which patients were initially treated with CRIXIVAN at a dose of < 2.4 g/day followed by 2.4 g/day. Study 019 (6/23/94-4/10/95) was a randomized comparison of CRIXIVAN 600 mg every 6 hours, CRIXIVAN plus zidovudine, and zidovudine alone. Table 6 shows the incidence of genotypic resistance at 24 weeks in these studies.

Table 6 Genotypic Resistance at 24 Weeks


Treatment Group Resistance to IDV
n/N*		 Resistance to ZDV
n/N*
IDV — —
   < 2.4 g/day 31/37 (84%) —
  2.4 g/day 9/21 (43%) 1/17 (6%)
IDV/ZDV 4/22 (18%) 1/22 (5%)
ZDV 1/18 (6%) 11/17 (65%)
* N - includes patients with non-amplifiable virus at 24 weeks who had amplifiable virus at week 0.
Brand Name: Crixivan
Generic Name: Indinavir Sulfate
Bookmark this page:

Privacy Policy

WebMD Daily

Get breaking medical news.

WebMD Symptom Checker - Start Here Ringworm Slideshow: Watch and Learn

HIV Test for Early DetectionHIV Test for Early Detection
There is a test that may help detect the virus sooner, so patients can start treatment much faster. See more WebMD Videos »